EO2 Concepts — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

EO2 Concepts is a commercial-stage medical device company focused on revolutionizing wound care through its proprietary Continuous Diffusion of Oxygen (CDO) technology. Its flagship OxyGeni System is an ISO-certified, FDA-cleared, portable oxygen generator that works with specialized dressings to deliver pure, humidified oxygen directly to the wound bed 24/7. The company has established a Federal Supply Schedule contract, enabling sales across the VA and broader U.S. federal healthcare system, and its therapy is supported by Level 1A clinical evidence demonstrating superior efficacy and cost-effectiveness compared to standards like negative pressure wound therapy. EO2 targets a large and growing chronic wound market driven by diabetes and an aging population.

Chronic Wound CareDiabetic Foot UlcersSurgical Wounds

Technology Platform

Continuous Diffusion of Oxygen (CDO) therapy delivered via a portable, wearable oxygen generator (OxyGeni System) and specialized diffusion dressings (OxySpur). The platform provides pure, humidified oxygen directly to the wound bed 24/7 to address hypoxia and promote healing.

Opportunities

The large and growing chronic wound market, driven by diabetes and aging demographics, presents a significant opportunity.

Securing a Federal Supply Schedule contract provides a major channel for growth within the VA and federal health systems.

Demonstrating cost-effectiveness versus standards like NPWT can drive rapid adoption by cost-conscious payers and integrated health networks.

Risk Factors

Intense competition from large, established players in the advanced wound care space poses a market penetration challenge.

Securing consistent and favorable reimbursement from private insurers beyond the federal system is critical and can be a lengthy, uncertain process.

Clinical adoption requires changing physician behavior and integrating a new therapy modality into standard practice.

Competitive Landscape

EO2 competes in the active wound therapy segment against dominant Negative Pressure Wound Therapy (NPWT) systems from companies like 3M (Acelity) and Smith & Nephew, as well as other topical oxygen therapies and advanced wound dressings. Its key differentiators are portability/24-7 use, robust clinical evidence (Level 1A), and a focus on cost-effectiveness and patient mobility compared to stationary hyperbaric oxygen therapy.

More companies in Drug Delivery & Formulation →More companies in United States →